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Background. Bacteremia and other invasive bacterial infections are common among children with cancer receiving intensive 
chemotherapy and in pediatric recipients of hematopoietic stem cell transplantation (HSCT). Systemic antibacterial prophylaxis is 
one approach that can be used to reduce the risk of these infections. Our purpose was to develop a clinical practice guideline (CPG) 
for systemic antibacterial prophylaxis administration in pediatric patients with cancer and those undergoing HSCT.
Methods. An international and multidisciplinary panel was convened with representation from pediatric hematology/oncology 
and HSCT, pediatric infectious diseases (including antibiotic stewardship), nursing, pharmacy, a patient advocate, and a CPG meth-
odologist. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to gen-
erate recommendations based on the results of a systematic review of the literature.
Results. The systematic review identified 114 eligible randomized trials of antibiotic prophylaxis. The panel made a weak rec-
ommendation for systemic antibacterial prophylaxis for children receiving intensive chemotherapy for acute myeloid leukemia and 
relapsed acute lymphoblastic leukemia (ALL). Weak recommendations against the routine use of systemic antibacterial prophylaxis 
were made for children undergoing induction chemotherapy for ALL, autologous HSCT and allogeneic HSCT. A strong recommen-
dation against its routine use was made for children whose therapy is not expected to result in prolonged severe neutropenia. If used, 
prophylaxis with levofloxacin was recommended during severe neutropenia.
Conclusions. We present a CPG for systemic antibacterial prophylaxis administration in pediatric cancer and HSCT patients. 
Future research should evaluate the long-term effectiveness and adverse effects of prophylaxis.
Keywords. practice guideline; bacterial infection; prevention; pediatric oncology; hematopoietic stem cell transplantation.
Bacteremia and other invasive bacterial infections are common 
among children with cancer receiving intensive chemo-
therapy and pediatric recipients of hematopoietic stem cell 
transplantation (HSCT) [1–3]. Systemic antibacterial prophy-
laxis is one approach that can be used to reduce the risk of these 
infections. Decision making regarding routine utilization of an-
tibacterial prophylaxis involves weighing measures of efficacy 
against potential negative consequences. Measures of efficacy 
of prophylaxis include reductions in fever, bacteremia, sepsis, 
infection-related mortality, and overall mortality. Potential neg-
ative consequences of prophylaxis include Clostridioides difficile 
infection, invasive fungal disease, drug toxicities, and antibiotic 
resistance [4–6]. 
While decision making regarding antibacterial prophylaxis 
will be informed by local bacterial resistance patterns and juris-
dictional drug availability, the development of a clinical practice 
 
Received 26 August 2019; editorial decision 22 October 2019; accepted 29 October 2019; pub-
lished online November 2, 2019.
Correspondence: L. Sung, Division of Haematology/Oncology, The Hospital for Sick Children, 
555 University Avenue, Toronto, ON, M5G1X8 Canada (lillian.sung@sickkids.ca).
Clinical Infectious Diseases®  2019;XX(XX):1–11
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/cid/ciz1082
HeadB/HeadA=HeadC=HeadB/HeadA=HeadC/HeadB
HeadC/HeadB=HeadD=HeadC/HeadB=HeadC/HeadB
HeadC=NList_dot_numeric1=HeadC=NList_dot_numeric
HeadC/HeadB=NList_dot_numeric1=HeadC/HeadB=NList_dot_numeric
HeadD=NList_dot_numeric1=HeadD=NList_dot_numeric
HeadD/HeadC=NList_dot_numeric1=HeadD/HeadC=NList_dot_numeric
SubBList2=NList_dot_numeric2=SubBList=NList_dot_numeric2
SubBList2=NList_dot_numeric=SubBList=NList_dot_numeric
NList_dot_numeric2=HeadB=NList_dot_numeric=HeadB
NList_dot_numeric3=HeadB=NList_dot_numeric=HeadB
NList_dot_numeric2=SubBList1=NList_dot_numeric=SubBList1
NList_dot_numeric3=SubBList1=NList_dot_numeric=SubBList1
SubBList3=HeadD=SubBList_Before_Head=HeadD
SubBList2=HeadD=SubBList_Before_Head=HeadD
SubBList2=HeadB=SubBList=HeadB
SubBList3=HeadB=SubBList=HeadB
HeadC=NList_dot_numeric1(2Digit)=HeadC=NList_dot_numeric(2Digit)
HeadC/HeadB=NList_dot_numeric1(2Digit)=HeadC/HeadB=NList_dot_numeric(2Digit)
HeadD=NList_dot_numeric1(2Digit)=HeadD=NList_dot_numeric(2Digit)
HeadD/HeadC=NList_dot_numeric1(2Digit)=HeadD/HeadC=NList_dot_numeric(2Digit)
SubBList2(2Digit)=NList_dot_numeric2(2Digit)=SubBList(2Digit)=NList_dot_numeric2(2Digit)
SubBList2(2Digit)=NList_dot_numeric(2Digit)=SubBList(2Digit)=NList_dot_numeric(2Digit)
NList_dot_numeric2(2Digit)=HeadB=NList_dot_numeric(2Digit)=HeadB
NList_dot_numeric3(2Digit)=HeadB=NList_dot_numeric(2Digit)=HeadB
NList_dot_numeric2(2Digit)=SubBList1(2Digit)=NList_dot_numeric(2Digit)=SubBList1(2Digit)
NList_dot_numeric3(2Digit)=SubBList1(2Digit)=NList_dot_numeric(2Digit)=SubBList1(2Digit)
SubBList3(2Digit)=HeadD=SubBList(2Digit)=HeadD
SubBList2(2Digit)=HeadD=SubBList(2Digit)=HeadD
SubBList2(2Digit)=HeadB=SubBList(2Digit)=HeadB
SubBList3(2Digit)=HeadB=SubBList(2Digit)=HeadB
Extract3=BList3=Extract1=BList3
BList3=Extract3=BList3=Extract3_0
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1082/5611087 by E-Library Insel user on 23 D
ecem
ber 2019
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
75
19
 
| 
do
wn
lo
ad
ed
: 
27
.1
.2
02
0
2 • cid 2019:XX (XX XXXX) • Lehrnbecher et al
guideline (CPG) may promote more standardized practice. 
A  CPG was developed by the American Society of Clinical 
Oncology and the Infectious Diseases Society of America for 
patients with cancer, but the target audience was restricted to 
adults [7]. Thus, there is a lack of guidance specifically for pe-
diatric patients.
Our objective was to create a CPG for systemic antibacterial 
prophylaxis administration in pediatric patients with cancer 
and recipients of HSCT.
METHODS
General Clinical Practice Guideline Development Approach
We convened a multidisciplinary and multinational CPG panel 
(details in Supplementary Appendices 1–3). The CPG was 
created using standard approaches for the development of ev-
idence-based CPGs [8] with the Appraisal of Guidelines for 
Research and Evaluation II instrument as a framework [9] (de-
tails in Supplementary Appendix 3).
Panel members developed the key clinical questions 
(Table 1) and identified and rated the importance of outcomes 
by consensus. The Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) approach was used 
to determine level of evidence and to formulate recommenda-
tions [10]. The level of evidence was rated as high, moderate, 
low, or very low based on certainty in treatment effects to the 
target population. Certainty was influenced by limitations in 
study design and consistency, precision, and directness of the 
data. Recommendations were either strong or weak. A strong 
recommendation was made when the benefits clearly out-
weighed the risks or vice versa, and thus, patients should, in 
general, receive (or not receive) the recommended interven-
tion as a matter of policy. Conversely, a weak recommenda-
tion was made when the benefits and risks of the intervention 
were closely matched or uncertain. In this setting, preferences 
and values should impact on intervention administration. In 
making recommendations, we considered efficacy, safety, costs, 
and resources.
Searching, Selecting and Describing the Evidence
To create this CPG, we focused on randomized trials, because, 
in general, they are at lower risk of bias than observational 
studies [11]. We recently conducted a systematic review of ran-
domized trials of systemic antibacterial prophylaxis and de-
scribed the efficacy and adverse effects associated with different 
systemic antibiotics [12]. We included both adult and pediatric 
trials in data synthesis. For this CPG, we updated the systematic 
review and separately summarized the pediatric data.
We included outcomes that were considered critical or im-
portant to recommendation decision making. Resistance was 
examined in 2 ways. First, resistance was examined in studies 
comparing an antibiotic against no antibiotic controls and 
was defined as resistance to the intervention antibiotic among 
bacteremia isolates. These results were synthesized. Second, 
we also described the results of all studies that systematically 
compared acquisition or prevalence of resistant colonizing or-
ganisms at the end of the treatment period between random-
ized groups. These results were not synthesized. We used the 
Cochrane Collaboration’s tool for assessing risk of bias in ran-
domized trials [13].
Statistical Analysis
Data were synthesized using the risk ratio (RR) as the effect 
measure with its 95% confidence interval (CI). In this meta-
analysis, an RR  less than  1 indicates that the intervention is 
better than the control. Treatment effects were estimated by the 
Mantel-Haenszel approach and weighted by inverse variance. 
Analysis used a random-effects model. For primary compari-
sons, we only synthesized outcomes when there were at least 3 
studies with available data.
We used subgroup analyses to determine whether prespecified 
characteristics explained heterogeneity in the treatment effect. 
We reported stratum effects and the P value for interaction if at 
least 2 studies reported an outcome within each stratum.
RESULTS
There were 114 publications included in the systematic re-
view; the flow diagram of study identification and selection is 
described in Supplementary Appendix 4. Characteristics of in-
cluded trials are presented in Supplementary Appendix 5. There 
were 4 comparisons amenable to funnel plots (data not shown). 
Publication bias was only suggested in the comparison of fluor-
oquinolone versus no antibiotic for the outcome of overall mor-
tality; Supplementary Appendix 6 shows the plot and results of 
the fill-and-trim approach.
Table 2 shows all evaluated interventions including the 3 
main comparisons against no antibiotic—namely, a fluoro-
quinolone, trimethoprim-sulfamethoxazole, and a cephalo-
sporin. Fluoroquinolone prophylaxis significantly reduced 
bacteremia (RR, .56; 95% CI, .41–.76), fever (RR, .70; 95% 
CI, .57–.86) and fever and neutropenia (FN; RR, .88; 95% CI, 
.82–.95). Fluoroquinolone prophylaxis was not significantly 
associated with more C.  difficile infection, invasive fungal di-
sease, and musculoskeletal toxicities, while it was significantly 
associated with more fluoroquinolone resistance in bacte-
remia isolates (RR, 3.35; 95% CI, 1.12–10.03). Trimethoprim-
sulfamethoxazole prophylaxis significantly reduced bacteremia 
(RR, .59; 95% CI, .41–.85) and infection-related mortality (RR, 
.61; 95% CI, .39–.94). However, it also increased trimethoprim-
sulfamethoxazole resistance in bacteremia isolates (RR, 2.91; 
95% CI, 1.65–5.12). Cephalosporin prophylaxis significantly 
reduced bacteremia (RR, .30; 95% CI, .16–.58). Table 2 also 
shows that rifampin and fluoroquinolone coadministration sig-
nificantly reduced bacteremia compared with fluoroquinolone 
alone (RR, .36; 95% CI, .17–.77).
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Supplementary Appendix 7 shows stratified analyses for a 
fluoroquinolone, trimethoprim-sulfamethoxazole, and a cepha-
losporin versus no antibiotic for the outcomes of bacteremia and 
infection-related mortality. In general, evaluated factors did not 
explain heterogeneity in the prophylaxis effect and differences 
were not observed based on treatment (chemotherapy, HSCT, 
or both), participant age, or risk of bacteremia in the control 
group. An exception was a marginally statistically significant in-
teraction (P = .04) for the comparison of cephalosporin versus 
no antibiotic for the outcome of bacteremia when stratified by 
the risk of bacteremia in the control group.
Table 3 shows the details of the 13 pediatric studies strati-
fied by the comparison group. Only 3 studies were conducted 
in the last 15  years; all compared a fluoroquinolone with no 
antibiotic. The largest and most recent study included 624 pa-
tients and stratified the analysis by (1) acute myeloid leukemia 
(AML) and relapsed acute lymphoblastic leukemia (ALL) and 
(2) myeloablative autologous and allogeneic HSCT [14]. All 
Table 1. Summary of Recommendations for Systemic Antibacterial Prophylaxis in Children With Cancer and Pediatric Hematopoietic Stem Cell Transplant 
Recipients
Health Questions and Recommendations
Strength of Recom-
mendation and Level 
of Evidence
Which pediatric patients with cancer and HSCT recipients (if any) should routinely receive systemic antibacterial prophylaxis? 
 1.Consider systemic antibacterial prophylaxis administration in children with AML and relapsed ALL receiving intensive 
chemotherapy expected to result in severe neutropenia (absolute neutrophil count <500/μL) for at least 7 days. 
 Remarks: This is a weak recommendation because the benefits of prophylaxis were closely balanced against its known 
and potential impacts on resistance. The panel valued what is known about efficacy and resistance outcomes of pro-
phylaxis administered within the finite time frame of a clinical trial among enrolled participants but also considered the 
less certain impacts of a universal prophylaxis strategy at both the patient and institutional level. Limiting prophylaxis 
to patient populations at highest risk of fever and neutropenia, bacteremia, and infection-related mortality could limit 
antibiotic utilization to those most likely to benefit from prophylaxis. Careful discussion with patients and families about 
the potential risks and benefits of prophylaxis is important. Understanding local resistance epidemiology is critical to the 
decision of whether to implement prophylaxis. 
Weak recommenda-
tion; high-quality 
evidence
 2.We suggest that systemic antibacterial prophylaxis not be used routinely for children receiving induction chemo-
therapy for newly diagnosed ALL. 
 Remarks: The panel acknowledged the paucity of direct contemporary randomized data applicable to children living in 
high-income countries. A recommendation to provide universal systemic prophylaxis to this group could have a sub-
stantial impact on institutions, given that ALL is the most common cancer diagnosis in children. There is great variability 
in duration of neutropenia and risk of bacteremia based on treatment protocol and patient-level characteristics. Further 
data are required to identify subgroups of pediatric patients with ALL who might particularly benefit from prophylaxis.
Weak recommenda-
tion; low-quality 
evidence
 3.Do not use systemic antibacterial prophylaxis for children whose therapy is not expected to result in severe neutro-
penia (absolute neutrophil count <500/μL) for at least 7 days. 
 Remarks: This strong recommendation was based on reduced chance of benefit combined with continued risk of harm 
associated with systemic antibacterial prophylaxis.
Strong recommen-
dation; moderate-
quality evidence
 4.We suggest that systemic antibacterial prophylaxis not be used routinely for children undergoing autologous HSCT 
 Remarks: This weak recommendation against routine use of antibacterial prophylaxis in autologous HSCT recipients 
acknowledged the risk reduction of bacteremia among this cohort. However, the panel believed that the lower baseline 
risk of bacteremia resulted in the impact on resistance (known and potential) outweighing the benefits. The moderate 
quality of evidence reflected the lack of granular data specifically in autologous HSCT recipients rather than HSCT pa-
tients as a group.
Weak recommenda-
tion; moderate-
quality evidence
 5.We suggest that systemic antibacterial prophylaxis not be used routinely for children undergoing allogeneic HSCT. 
 Remarks: The panel acknowledged that the granularity of available data did not allow a different recommendation for 
allogeneic compared with autologous HSCT recipients. However, the panel noted that allogeneic HSCT recipients often 
have preceding conditions that could be associated with prophylaxis (eg, AML or relapsed ALL) and have prolonged 
neutropenia during the HSCT process, which could influence the effectiveness and adverse effects associated with 
prophylaxis. 
Weak recommenda-
tion; moderate-
quality evidence
Which agents should be used for systemic antibacterial prophylaxis in children with cancer and HSCT recipients?
 6.Levofloxacin is the preferred agent if systemic antibacterial prophylaxis is planned. 
 Remarks: The strong recommendation to use levofloxacin is related to direct contemporary data in children and its 
microbiological spectrum of activity. If levofloxacin is not available or not able to be used, ciprofloxacin is an alternative, 
although lack of activity against gram-positive bacteria including viridans group streptococci may reduce the benefits 
of prophylaxis. Patients and families should be informed about potential short- and long-term fluoroquinolone-related 
adverse effects. Understanding local resistance epidemiology is critical to the decision of whether to implement fluor-
oquinolone prophylaxis. If fluoroquinolones are not available or cannot be used, providing no systemic antibacterial 
prophylaxis is an important option to consider. 
Strong recommen-
dation; moderate-
quality evidence
When should systemic antibacterial prophylaxis be started and stopped?  
 7.If systemic antibacterial prophylaxis is planned, we suggest that administration be restricted to the expected period of 
severe neutropenia (absolute neutrophil count <500/μL). 
 Remarks: This is a weak recommendation based on low-quality evidence because there are no trials that compared 
different start and stop criteria. In general, trials administered prophylaxis during severe neutropenia and thus this rec-
ommendation reflects the available evidence and the panel’s desire to minimize duration of prophylaxis administration.
Weak recommenda-
tion; low-quality 
evidence
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HSCT, hematopoietic stem cell transplantation.
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pediatric studies of trimethoprim-sulfamethoxazole versus no 
antibiotic were published in 1987 or earlier.
Supplementary Appendix 8 summarizes the studies that 
evaluated resistance in colonizing organisms at the comple-
tion of the study period. Among 3 fluoroquinolone versus 
no-antibiotic studies, the largest was the pediatric study that 
compared levofloxacin with no antibiotic [14]. This study 
evaluated the development of resistance to levofloxacin, 
cefepime, imipenem, and penicillin among a priori–defined 
stool commensals and did not show a difference between 
randomized groups. The other 2 studies also showed no differ-
ence in resistance to ciprofloxacin [27] or norfloxacin [28] as-
sociated with fluoroquinolone administration. In contrast, the 
2 trimethoprim-sulfamethoxazole versus no-antibiotic studies 
both suggested more-resistant colonizing organisms in the 
intervention group.
Table 1 presents health questions, recommendations, 
strength of recommendation, level of evidence, and remarks. 
Explanations are outlined below. Table 4 shows identified re-
search gaps.
Table 2. Synthesized Outcomes of All Systemic Antibacterial Prophylaxis Comparisons (Includes Pediatric and Adult Trials)
Comparison and Outcomes
Number of 
Studies RRa 95% CI I2, % P
Fluoroquinolone vs no antibioticb     
 Bacteremia 14 .56 .41 to .76 58 .0002
 Fever 9 .70 .57 to .86 71 .0008
 Neutropenic fever 8 .88 .82 to .95 0 .0008
 Infection-related mortality 16c .72 .45 to 1.16 0 .17
 Overall mortality 15c .86 .62 to 1.17 24 .34
 Clostridioides difficile infection 3 .62 .31 to 1.24 0 .17
 Invasive fungal disease 6 1.25 .75 to 2.08 0 .39
 Musculoskeletal adverse effects 3 .66 .39 to 1.13 0 .13
 Antibiotic resistanced 4 3.35 1.12 to 10.03 64 .03
Fluoroquinolone vs nonabsorbable antibiotic
 Fever 3 .98 .91 to 1.05 0 .50
 Infection-related mortality 3 .43 .18 to 1.05 0 .06
Trimethoprim-sulfamethoxazole vs no antibioticb
 Bacteremia 7 .59 .41 to .85 0 .005
 Fever 5 .77 .56 to 1.07 91 .11
 Infection-related mortality 13 .61 .39 to .94 0 .03
 Overall mortality 5 .61 .28 to 1.33 32 .21
 Invasive fungal disease 7 1.19 .43 to 3.27 27 .74
 Antibiotic resistanced 5 2.91 1.65 to 5.12 0 .0002
Cephalosporin vs no antibioticb
 Bacteremia 4 .30 .16 to .58 42 .0004
 Fever 4 .83 .71 to .98 65 .03
 Infection-related mortality 4c 1.03 .27 to 3.95 0 .96
 Overall mortality 3c NSP … …  
 Antibiotic resistanced 3c NSP … …  
Parenteral glycopeptide vs no antibioticb
 Bacteremia 3 .45 .08 to 2.66 84 .38
 Infection-related mortality 3 1.13 .30 to 4.23 10 .85
Fluoroquinolone vs trimethoprim-sulfamethoxazole
 Bacteremia 7 .86 .48 to 1.54 66 .60
 Fever 3 .65 .31 to 1.37 89 .26
 Infection-related mortality 6 1.10 .50 to 2.39 0 .82
 Invasive fungal disease 6 0.78 .35 to 1.75 0 .55
Rifampin and fluoroquinolone vs fluoroquinolone    
 Bacteremia 3 .36 .17 to .77 0 .008
 Infection-related mortality 3c NSP … …  
Overall mortality 3c NSP … …  
Abbreviations: CI, confidence interval; NSP, no synthesis possible; RR, risk ratio.
aRR <1 favors intervention.
bNo antibiotic includes no antibiotic prophylaxis and placebo control groups.
cOne or more studies had zero events in both arms.
dResistance was examined in studies comparing an antibiotic against no antibiotic controls and was defined as resistance to the intervention antibiotic among bacteremia isolates.
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Table 3. Details of Exclusively Pediatric Studies (N = 13)
First Author [Ref]
Year  
Published Study Characteristics Findings
Fluoroquinolone vs no antibiotic
 Alexander [14] 2018 Comparison: Levofloxacin vs no antibiotic 
Population: AML, relapsed ALL and HSCT 
Number of patients: 624 
Age range: 3–16 years 
Country: US and Canada 
Duration of antibiotic prophylaxis: (1) Patients with acute 
leukemia: 2 consecutive cycles of chemotherapy starting 
day 1 or 3; (2) HSCT recipients: 1 transplant procedure 
starting day −2 from stem cell infusion. Prophylaxis con-
tinued until: ANC >200/μL after nadir, day 60, or initiation 
of next chemotherapy cycle 
Bacteremia frequency in control: 
AML: 25/63 (40%) 
Relapsed ALL: 18/36 (50%) 
Autologous HSCT: 9/78 (12%) 
Allogeneic HSCT: 27/130 (21%) 
Systematic surveillance of colonizing organisms tested for 
resistance: Yes 
Other: Primary analysis stratified by acute leukemia vs 
HSCT
Bacteremia: Prophylaxis reduced bacteremia among 195 
leukemia patients (RD, 21.6%; 95% CI, 8.8–34.4%) but 
not among 418 HSCT recipients (RD, 6.3%; 95% CI, 
.3–13.0%). 
FN: In both groups combined, prophylaxis reduced FN (RD, 
10.8%; 95% CI, 4.2–17.5%). 
Mortality: No deaths were attributed to bacterial infection. 
CDI and IFD: Prophylaxis did not increase Clostridium difficile–
associated diarrhea (RD, 2.9%; 95% CI, −0.1% to 5.9%) or 
IFD (RD, −1.0%; 95% CI, −3.4% to 1.5%). 
Resistance: Qualitatively, higher rate of resistance in bacte-
remia isolates in prophylaxis compared with control group. 
Significantly less exposure to aminoglycosides, third- or 
fourth-generation cephalosporin, and antibiotics commonly 
used to treat FN in prophylaxis group.
 Laoprasopwattana 
[15]
2013 Comparison: Ciprofloxacin vs placebo 
Population: Lymphoma and ALL undergoing induction or 
consolidation 
Number of patients: 95 
Age range: 0.25–18 years 
Country: Thailand 
Duration of antibiotic prophylaxis: Beginning within 5 days 
after starting chemotherapy and was discontinued when 
ANC of 1000/μL after 2 weeks of chemotherapy. Median 
duration of prophylaxis was 18 days in ciprofloxacin 
group and 10 days in placebo group. 
Bacteremia frequency in control: 1/50 (2%) 
Systematic surveillance of colonizing organisms tested for 
resistance: Patient-level data not reported
Bacteremia: In the prophylaxis group, 2/45 developed bacte-
remia vs 1/50 receiving placebo. 
FN and fever: In those who developed neutropenia, prophy-
laxis reduced the occurrence of fever (RD, −23.0%; 95% 
CI, −45.0% to −9.0%). In patients with ALL, prophylaxis 
reduced the occurrence of fever in those undergoing induc-
tion (RD, −23.7%; 95% CI, −45.6% to −1.8%), but not in 
consolidation (RD, 9.8%; 95% CI, −17.8% to 37.5%). 
CDI and IFD: Not reported. 
Mortality: Not reported. 
Resistance: In all 3 cases of bacteremia, the causative or-
ganism was susceptible to ciprofloxacin. 
 Widjajanto [16] 2013 Comparison: Ciprofloxacin vs placebo 
Population: Induction ALL 
Number of patients: 110 
Age range: 1–14 years 
Country: Indonesia 
Duration of antibiotic prophylaxis: From start of chemo-
therapy until completion of induction treatment 
Bacteremia frequency in control: Not reported 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
Other: At baseline, 37/110 were undernourished; abandon-
ment as a reason for induction failure: 10/110
Bacteremia: Not reported. 
Fever: In the prophylaxis group, 29/58 had at least 1 fever 
compared with 17/52 in the placebo group (P = .07). 
Mortality: In the prophylaxis group, 11/58 died compared with 
3/52 in the placebo group (P = .05). 
CDI and IFD: Not reported. 
Resistance: Not reported. 
Other: Clinical sepsis occurred in 29/58 patients receiving pro-
phylaxis and in 20/52 patients receiving placebo (P = .22). 
Trimethoprim-sulfamethoxazole vs no antibiotic
 Van Eys [17] 1987 Comparison: TMP-SMX vs no antibiotic 
Population: Newly diagnosed ALL 
Number of patients: 126 
Age range: Not reported 
Country: US 
Duration of antibiotic prophylaxis: Starting week 5 of 
therapy and continuing for 3 years or until relapse 
Bacteremia frequency in control: Not reported 
Systematic surveillance of colonizing organisms tested for 
resistance: No
Bacteremia: Not reported. 
FN and fever: Not reported. 
Mortality: One infectious death occurred in each group. 
CDI and IFD: Not reported. 
Resistance: Not reported. 
Other: No effect of prophylaxis on disease-free survival at 
3 years.
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First Author [Ref]
Year  
Published Study Characteristics Findings
 Goorin [18] 1985 Comparison: TMP-SMX vs placebo 
Population: Newly diagnosed ALL (induction, consolidation, 
early maintenance) 
Number of patients: 61 
Age range: 1–16 years 
Country: US 
Duration of antibiotic prophylaxis: Immediately after diag-
nosis and continued daily during induction, intensifica-
tion, and early maintenance phases for ~40 weeks 
Bacteremia frequency in control: Not reported 
Systematic surveillance of colonizing organisms tested for 
resistance: Only for patients in the first year of the study 
due to difficulties collecting routine stool samples
Bacteremia: In the prophylaxis group there were fewer epi-
sodes of bacteremia compared with placebo (0 vs 5). 
FN and fever: Not reported. 
Mortality: One death occurred in the study and it was due to 
an infection in the placebo group. 
CDI and IFD: Not reported. 
Resistance: In the prophylaxis group, 5/19 patients’ stool sur-
veillance cultures developed gram-negative bacilli resistant 
to TMP-SMX compared with 0/18 in the placebo group 
(P = .05).
 Kovatch [19] 1985 Comparison: TMP-SMX vs placebo 
Population: Induction ALL and AML; relapsed ALL and solid 
tumors 
Number of patients: 91 
Age range: 0.25–17 years 
Country: US 
Duration of antibiotic prophylaxis: Started day 2 or 3 of in-
duction chemotherapy. Continued in the leukemia group 
until remission and in the solid tumor group until 60 days 
following chemotherapy initiation. 
Bacteremia frequency in control: Overall not reported. In 
the subgroup that developed neutropenia: 
Induction leukemia: 6/26 (23%) 
Reinduction leukemia: 0/2 (0%) 
Solid tumors: 1/7 (14%) 
Systematic surveillance of colonizing organisms tested for 
resistance: No
Bacteremia: Bacteremia reported for the subgroup of patients 
that developed neutropenia. In this subgroup, 1/39 re-
ceiving prophylaxis vs 7/35 in the placebo group developed 
bacteremia. 
Fever: In the prophylaxis group 14/43 had a febrile episode 
compared with 25/48 in the placebo group (P = .10). 
Mortality: Two infection-related deaths occurred, both in the 
placebo group. 
CDI and IFD: No IFD occurred in either group. CDI not re-
ported. 
Resistance: In the neutropenic subgroup developing bacte-
remia, the 1 case of bacteremia in the prophylaxis group 
and 1/7 cases in the placebo group were resistant to 
TMP-SMX.
 Lange [20] 1984 Comparison: TMP-SMX and nystatin vs no antibiotic 
Population: Newly diagnosed ALL (induction) 
Number of patients: 67 
Age range: 0.5–16 years 
Country: US 
Duration of antibiotic prophylaxis: Not clear 
Bacteremia frequency in control: 5/25 (20%) 
Systematic surveillance of colonizing organisms tested for 
resistance: No
Bacteremia: In the prophylaxis group, 2/25 developed bacte-
remia vs 5/35 in the no-antibiotic group. 
Fever: Not reported. 
Mortality: There was 1 infection-related death in each group. 
CDI and IFD: One IFD occurred in the control group. CDI not 
reported. 
Resistance: Both cases of bacteremia in the prophylaxis 
group were resistant to TMP-SMX. No information on the 
control group.
 Inoue [21] 1982 Comparison: TMP-SMX vs placebo 
Population: Induction, maintenance and relapsed ALL and 
AML 
Number of patients: 102 
Age range: Not reported 
Country: Japan 
Duration of antibiotic prophylaxis: Not clear 
Systematic surveillance of colonizing organisms tested for 
resistance: Yes 
Bacteremia frequency in control: Not reported
Bacteremia: Narratively reported bacterial sepsis occurred 
less frequently in the group receiving prophylaxis. 
Fever: Not reported. 
Mortality: Not reported. 
CDI and IFD: Not reported. 
Resistance: Not reported.
Fluoroquinolone vs trimethoprim-sulfamethoxazole 
 Cruciani [22] 1989 Comparison: Norfloxacin vs TMP-SMX 
Population ALL, AML, lymphoma, neuroblastoma 
Number of patients: 44 
Age range: Not reported 
Country: Italy 
Duration of antibiotic prophylaxis: Children receiving in-
duction remission chemotherapy. Discontinued when 
neutrophil count exceeded 1000/μL. 
Bacteremia frequency in control: Not applicable, as prophy-
laxis control group 
Systematic surveillance of colonizing organisms tested for 
resistance: Yes
Bacteremia: In the norfloxacin group, 4/21 developed bacte-
remia vs 4/23 in the TMP-SMX group. 
Fever: In norfloxacin group, 9/21 had at least 1 fever vs 20/23 
in the TMP-SMX group. 
Mortality: There was 1 infection-related death in each group. 
CDI and IFD: Not reported. 
Resistance: Did not report number of patients with newly 
developed resistance.
Table 3. Continued
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Recommendation 1: Consider systemic antibacterial pro-
phylaxis administration in children with AML and relapsed 
ALL receiving intensive chemotherapy expected to result 
in severe neutropenia (absolute neutrophil count <500/μL) 
for at least 7 days.
Weak recommendation, high-quality evidence
Explanation: The panel deliberated the overall analyses, direct 
pediatric data, and resistance information in formulating this 
recommendation. Direct data for pediatric patients with AML 
and relapsed ALL were available in the trial that compared 
levofloxacin with no antibiotic where the risk of bacteremia in 
the control group was 43.4% [14]. Levofloxacin prophylaxis sig-
nificantly reduced bacteremia in this group (RR, .50; 95% CI, 
.32–.78). Prophylaxis also significantly reduced C. difficile–posi-
tive tests, and exposure to broad-spectrum antibiotics including 
aminoglycosides, third- and fourth-generation cephalosporins, 
and antibiotics used as empiric therapy for FN among all pa-
tients (Table 3). The panel agreed that absolute reductions in 
bacteremia and FN were meaningful. Effects were consistent 
across analyses and populations, increasing quality of evidence. 
Further, the panel deliberated the trade-off of greater exposure 
First Author [Ref]
Year  
Published Study Characteristics Findings
Others    
 Castagnola [23] 2003 Comparison: Amoxicillin/clavulanate vs placebo 
Population: Leukemia, lymphoma, or solid tumor 
Number of patients: 167 
Age range: 0–18 years 
Country: Italy 
Duration of antibiotic prophylaxis: Started when neutro-
penia developed during chemotherapy. Continued until 
bone marrow recovery (generally 500–1000/μL). 
Bacteremia frequency in control: Not applicable, as prophy-
laxis control group 
Bacteremia frequency in control: 5/83 (6%) 
Systematic surveillance of colonizing organisms tested for 
resistance: No
Bacteremia: In the prophylaxis group, 3/84 developed bacte-
remia vs 5/83 in the placebo group. 
Fever: In the prophylaxis group, 23/84 had fever vs. 31/83 in 
the group receiving no prophylaxis.  
Mortality: One death occurred in the study and it was due to 
an infection in the prophylaxis group. 
CDI and IFD: Not reported. 
Resistance: Not reported.
 Avril [24] 1994 Comparison: Ceftazidime and teicoplanin vs no antibiotic 
Population: Autologous HSCT 
Number of patients: 60 
Age range: 2–16 years 
Country: France 
Duration of antibiotic prophylaxis: Started 3–4 days before 
the onset of aplasia and continued until aplasia resolved. 
Bacteremia frequency in control: 7/29 (24%) 
Systematic surveillance of colonizing organisms tested for 
resistance: No
Bacteremia: In the prophylaxis group, 2/30 developed bacte-
remia vs 7/29 in the group receiving no prophylaxis. 
Fever: In the prophylaxis group, 28/30 had fever vs 29/29 in 
the group receiving no prophylaxis. 
Mortality: Not reported. 
CDI and IFD: Not reported. 
Resistance: Not reported.
 Arico [25] 1992 Comparison: TMP-SMX daily vs TMP-SMX 3 days a week 
Population: Maintenance ALL 
Number of patients: 77 
Age range: Not reported 
Country: Italy 
Duration of antibiotic prophylaxis: Not clear 
Bacteremia frequency in control: Not applicable, as prophy-
laxis control group 
Systematic surveillance of colonizing organisms tested for 
resistance: No
Bacteremia: Not reported. 
Fever: Not reported. 
Mortality: Not reported. 
CDI and IFD: Not reported. 
Resistance: Not reported.
 Rossi [26] 1987 Comparison: TMP-SMX daily vs TMP-SMX 3 days a week 
Population: Newly diagnosed and relapsed ALL or AML 
Number of patients: 97 
Age range: 0.9–15 years 
Country: Italy 
Duration of antibiotic prophylaxis: For the duration of 
antineoplastic treatment starting from the first day of 
induction. Median duration of prophylaxis was 144 days 
in the daily group and 110 days in the control group. 
Bacteremia frequency in control: Not applicable, as prophy-
laxis control group. 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
Bacteremia: Two episodes of bacteremia in each group. 
Fever: Not reported. 
Mortality: Not reported. 
CDI and IFD: Not reported. 
Resistance: Not reported. 
Other: The number of severe infections and side effects were 
similar between the groups.
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANC, absolute neutrophil count; CI, confidence interval; CDI, Clostridium difficile infection; FN, fever and 
neutropenia; HSCT, hematopoietic stem cell transplantation; IFD, invasive fungal disease; NR, not reported; RD, risk difference; Ref, reference; TMP-SMX, trimethoprim-sulfamethoxazole; 
US, United States.
Table 3. Continued
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to prophylactic antibiotics against decreasing exposure to other 
broad-spectrum antibiotics. These considerations led to a rec-
ommendation for systemic antibacterial prophylaxis in this 
population.
However, the panel had major reservations about making a 
strong recommendation for systemic antibacterial prophylaxis. 
First was the clear signal of increased antibiotic resistance in 
bacteremia isolates associated with prophylaxis (Table 2). The 
panel was concerned that widespread adoption of prophylaxis 
could increase resistance to an extent that would preclude uti-
lization of that antibiotic either for prophylaxis or treatment 
[29, 30]. Second, the panel highlighted that the evidence was 
obtained from studies in which selected patients (those ran-
domized to the intervention group) were administered pro-
phylaxis over a finite period of the clinical trial. The impacts 
of a universal prophylaxis strategy over multiple treatment 
periods at both the patient and institutional level are uncertain 
[29]. Third, the panel discussed the potential for emergence of 
cross-resistance beyond the administered prophylactic agent. 
Understanding local resistance epidemiology is critical to the 
decision of whether to implement prophylaxis. Finally, the syn-
thesis failed to show that systemic antibiotic prophylaxis re-
duced overall mortality.
The panel discussed the possibility of alternative approaches 
to antibacterial prophylaxis, such as optimizing management of 
bacteremia/sepsis. However, these approaches were not thought 
to be mutually exclusive as prevention of bacteremia and 
improving the management of bacteremia/sepsis are both de-
sirable. It is also worth noting that, in recent periods, mortality 
due to bacteremia in pediatric high-risk populations is very rare 
and no deaths were reported in the large pediatric levofloxacin 
prophylaxis trial [14].
Recommendation 2: We suggest that systemic antibac-
terial prophylaxis not be used routinely for children re-
ceiving induction chemotherapy for newly diagnosed ALL.
Weak recommendation, low-quality evidence
Explanation: In terms of studies conducted within the last 
15 years, only 2 trials included children undergoing induction 
therapy for ALL. One study comparing ciprofloxacin versus 
placebo was conducted in Thailand [15]; the prevalence of bac-
teremia in the control group was 2%. The second study was 
conducted in Indonesia and also compared ciprofloxacin with 
placebo [16]. At baseline, 37 of 110 children were undernour-
ished and abandonment during induction occurred in 10 of 110 
children. The panel believed that neither of these studies were 
applicable to the setting of induction ALL in high-income coun-
tries, where the risk of bacteremia associated with contemporary 
induction ALL regimens is typically greater than 10% [31–33].
The panel recognized that a recommendation for adminis-
tration of systemic antibacterial prophylaxis would have a large 
impact since ALL is the most common pediatric cancer diag-
nosis. The weak recommendation against routine prophylaxis 
was based on the lower risk of bacteremia in the absence of pro-
phylaxis (when compared with children with AML and relapsed 
ALL) [34], the uncertain benefit in this specific population, and 
the more certain impact on resistance in bacteremia isolates. 
However, the panel also recognized heterogeneity in the risk of 
FN and bacteremia based on treatment protocol and patient-
related factors such as Down syndrome. Further data are re-
quired to identify subgroups of pediatric patients with ALL who 
might particularly benefit from prophylaxis and to describe the 
effectiveness of prophylaxis in these groups. The effectiveness 
of prophylaxis is even more uncertain during other phases of 
intensive ALL treatment outside of induction. Consideration 
could be given to extending this recommendation to blocks of 
intensive ALL chemotherapy outside of induction associated 
with prolonged severe neutropenia.
Recommendation 3: Do not use systemic antibacterial 
prophylaxis for children whose therapy is not expected 
to result in severe neutropenia (absolute neutrophil count 
<500/μL) for at least 7 days.
Strong recommendation, moderate-quality evidence
Table 4. Key Knowledge Gaps Related to Systemic Antibacterial Prophylaxis Among Children With Cancer and Pediatric Hematopoietic Stem Cell 
Transplantation Recipients
To determine whether the effectiveness of systemic antibacterial prophylaxis changes when administered over a prolonged period of time within individuals 
and within institutions
To determine the consequences of a universal systemic antibacterial prophylaxis strategy within individuals (both those receiving and not receiving prophylaxis) 
and within institutions
To describe subgroups of patients undergoing induction chemotherapy for acute lymphoblastic leukemia at higher risk of bacteremia and infection-related mor-
tality
To determine the risks and benefits of systemic antibacterial prophylaxis in children undergoing induction chemotherapy for acute lymphoblastic leukemia
To determine the risks and benefits of systemic antibacterial prophylaxis for children with acute lymphoblastic leukemia receiving intensive chemotherapy 
phases other than induction, such as delayed intensification
To identify subgroups of patients at higher risk of bacteremia and infection-related mortality (other than those identified in this clinical practice guideline such as 
children with solid tumor receiving intensive chemotherapy), such that the risks and benefits of systemic antibacterial prophylaxis can be considered
To determine the cost-effectiveness of antibacterial prophylaxis in different patient populations
To compare the risks and benefits of levofloxacin and ciprofloxacin prophylaxis 
To identify facilitators of guideline-concordant care
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Explanation. The relative effect of prophylaxis to reduce bac-
teremia did not differ based on control-group bacteremia risk 
(Supplementary Appendix 7). However, the panel noted that the 
absolute risk reduction becomes clinically unimportant when 
the risk of bacteremia decreases sufficiently. Thus, for patients 
whose therapy is not expected to result in prolonged severe 
neutropenia, the panel made a strong recommendation against 
systemic antibacterial prophylaxis because patients would be 
exposed to adverse effects of prophylaxis without realizing clin-
ically important benefits.
Recommendation 4: We suggest that systemic antibacte-
rial prophylaxis not be used routinely for children under-
going autologous HSCT.
Weak recommendation, moderate-quality evidence
Explanation. The rationale for this weak recommendation against 
routine use of antibacterial prophylaxis is similar to that sup-
porting Recommendations 2 and 3: that is, a smaller clinical ben-
efit in comparison to children with AML and relapsed ALL related 
to the lower risk of bacteremia in the absence of prophylaxis, and 
the same anticipated downsides, including impact on resistance. 
The risk of bacteremia was derived from the recent pediatric trial 
[14] that showed a control-group risk of 11.5% among autologous 
HSCT recipients compared with 43.4% among the AML and re-
lapsed ALL group (Table 3). The lack of interaction observed by 
treatment group (chemotherapy, HSCT, or both) (Supplementary 
Appendix 7) and the direct evidence from the recent pediatric trial 
that included autologous HSCT patients [14] (Table 3) support 
similar relative effects of prophylaxis on infection outcomes in 
this population. However, because the baseline risk of bacteremia 
is lower in HSCT patients compared to patients with AML and 
relapsed ALL, the absolute risk reduction is consequently smaller. 
The panel concluded that this smaller clinical benefit was out-
weighed by the impact of prophylaxis on resistance.
There was debate about factors in autologous HSCT patients 
that could change the balance of risks and benefits. The shorter 
duration of neutropenia in autologous HSCT with briefer ex-
posure to prophylaxis may diminish the impact on resistance. 
However, the use of tandem autologous HSCTs and resultant 
multiple cycles of prophylaxis could increase the impact on re-
sistance. The panel also noted that autologous HSCT is often the 
final intensive course of treatment and that this sequence could 
reduce the impact of resistance at the individual level, although 
this would not alter the impact at the institutional level. While 
the panel made a weak recommendation against prophylaxis, 
institutions or providers may opt for prophylaxis if the reduc-
tion in bacteremia risk enables transition to outpatient therapy.
Recommendation 5: We suggest that systemic antibacte-
rial prophylaxis not be used routinely for children under-
going allogeneic HSCT.
Weak recommendation, moderate-quality evidence
Explanation: The panel acknowledged that the granularity 
of available data did not allow a different recommendation 
for allogeneic compared with autologous HSCT recipients. 
Thus, the evidence base that underlies this recommendation 
is very similar to that made for autologous HSCT. Further, as 
these patients are routinely managed in hospital during the 
high-risk period, there is opportunity for very early empiric 
antibiotic administration and supportive care to reduce com-
plications of bacteremia and severe sepsis. The panel noted 
that allogeneic HSCT recipients often have preceding condi-
tions that could be associated with prophylaxis (eg, AML or 
relapsed ALL), have prolonged neutropenia during the HSCT 
process, and are at risk of graft-versus-host disease and sub-
sequent intensive immunosuppressive therapies, which could 
influence the effectiveness and adverse effects associated with 
prophylaxis.
Recommendation 6: Levofloxacin is the preferred agent if 
antibacterial prophylaxis is planned.
Strong recommendation, moderate-quality evidence
Explanation: If used, prophylaxis should be directed at 
pathogens that are responsible for severe or difficult-
to-treat infections. The strong recommendation to use 
levofloxacin if antibacterial prophylaxis is planned was 
based on recent trials, direct data, and the microbiolog-
ical spectrum of activity. Although fluoroquinolones, 
trimethoprim-sulfamethoxazole, and cephalosporins were 
all effective at reducing bacteremia, recent trials focused on 
fluoroquinolones. Trimethoprim-sulfamethoxazole was not 
recommended because it has the potential for increased re-
sistance in colonizing organisms (Supplementary Appendix 
8), has a risk of drug-induced myelosuppression [35], and 
the studies were at a higher risk of bias (Supplementary 
Appendix 7). Levofloxacin, in particular, was preferred re-
lated to the recent large pediatric trial showing benefits [14] 
and broad-spectrum activity against important organisms in 
pediatric high-risk populations.
The panel noted that levofloxacin or pediatric-friendly 
levofloxacin dosage forms may not be available in all coun-
tries. The availability of oral suspension will impact on fea-
sibility of levofloxacin administration in young children 
treated as outpatients. If levofloxacin is not able to be used, 
ciprofloxacin is an alternative, although reduced activity rel-
ative to levofloxacin against gram-positive bacteria, including 
viridans group streptococci, may reduce the benefits of pro-
phylaxis. Understanding local resistance epidemiology is crit-
ical to the decision of whether to implement fluoroquinolone 
prophylaxis.
Although the data supported administration of a fluoro-
quinolone if systematic antibacterial prophylaxis is planned, 
the panel was concerned about reported adverse effects asso-
ciated with these agents and levofloxacin in particular [6, 36]. 
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Patients and families should be informed about potential short- 
and long-term fluoroquinolone-related adverse effects prior to 
administration and this information may lead to some families 
choosing against prophylaxis. If fluoroquinolones are not avail-
able or cannot be used, providing no systemic antibacterial pro-
phylaxis is an important option to consider.
Recommendation 7: If antibacterial prophylaxis is 
planned, we suggest that administration be restricted to 
the expected period of severe neutropenia (absolute neu-
trophil count <500/μL).
Weak recommendation, low-quality evidence
Explanation: There are no randomized trials to support dif-
ferent approaches to initiation and discontinuation of systemic 
antibacterial prophylaxis in this patient population. Thus, this 
is a weak recommendation based on low-quality evidence. This 
recommendation reflects the available evidence and the panel’s 
desire to minimize duration of prophylaxis administration.
DISCUSSION
In this CPG, we present recommendations for the adminis-
tration of systemic antibacterial prophylaxis in pediatric pa-
tients with cancer and those receiving HSCT. Several issues 
were repeatedly emphasized during panel discussions. First 
was the weighing of short-term benefits in reducing bacte-
remia and FN balanced against the more long-term potential 
consequences of increasing resistance rates in patients and 
within institutions. If prophylaxis is implemented, institutions 
should closely monitor resistance rates over time. Second was 
the acknowledgment that the trials, while critical to making 
recommendations, do not reflect consequences of a universal 
prophylaxis strategy either related to effectiveness or to risks 
of prophylaxis. Third, although the panel recommended, 
based on available trials, a fluoroquinolone as the agent for 
prophylaxis, concern was raised about the adverse effect pro-
file. Patients and families will need to be informed about these 
risks, and these outcomes require further study in centers 
where prophylaxis is instituted.
A limitation of the evidence base is that the number of pe-
diatric trials precluded restricting the synthesis to children. In 
addition, trials were not conducted in the era of increasing use 
of immunotherapy and more data in this setting are required. 
As with all CPGs, establishing implementation processes in-
cluding local adaptation are important steps. Institutions will 
also need to decide what threshold of antibacterial resistance 
would mandate a change in policy regarding systemic antibac-
terial prophylaxis.
In summary, we present a CPG for systemic antibacterial 
prophylaxis administration in pediatric patients with cancer 
and recipients of HSCT. Future research should evaluate the 
long-term effectiveness and adverse effects of prophylaxis.
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